Ebihara T - Search Results

1

Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.

Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, Katoh M, Yokoi T, Asahi S. Takeuchi T, et al. Among authors: ebihara t. Pharm Res. 2006 Jul;23(7):1460-72. doi: 10.1007/s11095-006-0285-7. Epub 2006 Jun 21. Pharm Res. 2006. PMID: 16779700

2

Marked impact of P-glycoprotein on the absorption of TAK-427 in rats.

Takeuchi T, Nonaka M, Yoshitomi S, Higuchi T, Ebihara T, Maeshiba Y, Kawase M, Asahi S. Takeuchi T, et al. Among authors: ebihara t. Biopharm Drug Dispos. 2008 Sep;29(6):311-23. doi: 10.1002/bdd.609. Biopharm Drug Dispos. 2008. PMID: 18651556

3

Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans.

Ebihara T, Takeuchi T, Moriya Y, Tagawa Y, Kondo T, Moriwaki T, Asahi S. Ebihara T, et al. Drug Res (Stuttg). 2016 Jun;66(6):316-23. doi: 10.1055/s-0035-1569441. Epub 2016 Mar 24. Drug Res (Stuttg). 2016. PMID: 27011383

4

Species differences of organic anion transporters involved in the renal uptake of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, between rats and dogs.

Takeuchi T, Jinno F, Ebihara T, Moriya Y, Kadotani R, Tagawa Y, Kondo T, Itoh T, Asahi S. Takeuchi T, et al. Among authors: ebihara t. Biopharm Drug Dispos. 2013 May;34(4):236-46. doi: 10.1002/bdd.1841. Epub 2013 May 7. Biopharm Drug Dispos. 2013. PMID: 23529922

5

Pharmacokinetics of TAK-475, a Squalene Synthase Inhibitor, in Rats and Dogs.

Ebihara T, Teshima K, Kondo T, Tagawa Y, Moriwaki T, Asahi S. Ebihara T, et al. Drug Res (Stuttg). 2016 Jun;66(6):287-92. doi: 10.1055/s-0035-1569407. Epub 2016 Feb 2. Drug Res (Stuttg). 2016. PMID: 26839207

6

Absorption of TAK-491, a new angiotensin II receptor antagonist, in animals.

Kawaguchi N, Ebihara T, Takeuchi T, Morohashi A, Yamasaki H, Tagawa Y, Takahashi J, Kondo T, Asahi S. Kawaguchi N, et al. Among authors: ebihara t. Xenobiotica. 2013 Feb;43(2):182-92. doi: 10.3109/00498254.2012.708797. Epub 2012 Aug 7. Xenobiotica. 2013. PMID: 22867273

7

The effect of elevated α₁-acid glycoprotein on the pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, in rats.

Ebihara T, Shimizu H, Yamamoto M, Higuchi T, Jinno F, Tagawa Y. Ebihara T, et al. Xenobiotica. 2019 May;49(5):584-590. doi: 10.1080/00498254.2018.1480817. Epub 2018 Jun 25. Xenobiotica. 2019. PMID: 29790816

8

Differences in nonclinical pharmacokinetics between species and prediction of human pharmacokinetics of TAK-272 (SCO-272), a novel orally active renin inhibitor.

Ebihara T, Nishihara M, Takahashi J, Jinno F, Tagawa Y. Ebihara T, et al. Biopharm Drug Dispos. 2018 Mar;39(3):175-183. doi: 10.1002/bdd.2124. Biopharm Drug Dispos. 2018. PMID: 29474740

9

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury.

Wolenski FS, Zhu AZX, Johnson M, Yu S, Moriya Y, Ebihara T, Csizmadia V, Grieves J, Paton M, Liao M, Gemski C, Pan L, Vakilynejad M, Dragan YP, Chowdhury SK, Kirby PJ. Wolenski FS, et al. Among authors: ebihara t. Toxicol Sci. 2017 May 1;157(1):50-61. doi: 10.1093/toxsci/kfx018. Toxicol Sci. 2017. PMID: 28108665 Free PMC article.

10

Characterization of Fasiglifam-Related Liver Toxicity in Dogs.

Kogame A, Moriya Y, Mori I, Pan L, Morohashi A, Ebihara T, Fukui H, Tagawa Y, Benet LZ. Kogame A, et al. Among authors: ebihara t. Drug Metab Dispos. 2019 May;47(5):525-534. doi: 10.1124/dmd.118.084889. Epub 2019 Feb 14. Drug Metab Dispos. 2019. PMID: 30765394

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

441 results

Search Page

Filters